跳至主要内容
临床试验/NCT00351052
NCT00351052已完成3 期

A 24-Week, Randomized, Multicenter, Parallel-Group, Double-Blind, Vehicle-Controlled Study on Pimecrolimus Cream 1% Assessing the Steroid-Sparing Effect in the Long Term Management of Pediatric Patients With Severe Atopic Dermatitis

Novartis0 个研究点目标入组 184 人开始时间: 2001年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Novartis
入组人数
184
主要终点
Corticoid-sparing effect of pimecrolimus cream 1%

研究概览

简要总结

This study will investigate the steroid sparing effect of pimecrolimus cream 1% in pediatric atopic dermatitis

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
2 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Outpatients aged 2 to < 18 years with severe AD (score 8 or 9 according to Rajka and Langeland)
  • responded to 21 days of treatment with prednicarbate cream 0.25% during screening phase

排除标准

  • Patients who had received phototherapy, systemic or topical therapy or systemic corticosteroids shortly prior to study

研究组 & 干预措施

1

Experimental

Pimecrolimus

干预措施: Pimecrolimus (Drug)

2

Placebo Comparator

Vehicle

干预措施: Placebo (Drug)

结局指标

主要结局

Corticoid-sparing effect of pimecrolimus cream 1%

次要结局

  • safety of pimecrolimus cream 1%
  • atopic dermatitis control
  • quality of life

研究者

发起方
Novartis
申办方类型
Industry

相似试验